RenalDose

Evidence Library — Renal Dosing References

Equations, guidelines, and key publications curated for clinical practice

Renal Function Estimation Equations Explained

1 Cockcroft-Gault (1976)
CrCl = [(140 - age) × weight] / (72 × SCr) × 0.85 if female
When to use: Drug label specifies Cockcroft-Gault; most legacy drugs with CrCl-based dosing adjustments.
Limitations: Not calibrated to IDMS-standardized serum creatinine; overestimates GFR in obese patients; underestimates in the elderly and cachectic populations. Does not account for tubular secretion of creatinine.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
2 BMI-guided Cockcroft-Gault
CrCl = [(140 - age) × weight*] / (72 × SCr) × 0.85 if female Weight selection by BMI: BMI < 18.5 → Actual Body Weight (ActBW) BMI 18.5-30 → Ideal Body Weight (IBW) BMI > 30 → Adjusted BW = IBW + 0.4 × (ActBW - IBW)
When to use: Drug label specifies Cockcroft-Gault without a specific weight recommendation. The BMI-guided approach selects the most clinically appropriate body weight to minimize bias.
Rationale: Underweight patients need actual weight (to avoid underestimation); normal BMI patients use IBW (CG was originally validated with lean weight); obese patients use an adjusted weight with 40% correction factor to avoid overestimation.
Algendy AF et al. Estimation of renal functions for drug dosing: a narrative review. (RenalDose research)
3 CKD-EPI 2021 (Race-free)
eGFR = 142 × min(SCr/k, 1)^a × max(SCr/k, 1)^-1.200 × 0.9938^age × 1.012 [if female] Where: k = 0.7 (female) or 0.9 (male) a = -0.241 (female) or -0.302 (male)
When to use: Recommended by NKF/KDIGO 2024; FDA 2024 guidance for new PK studies. Does not require weight or height. Result is indexed to BSA (mL/min/1.73 m²).
Limitations: Indexed to BSA (mL/min/1.73 m²), which may not reflect absolute clearance in patients with extreme body size. May overestimate GFR in elderly patients. Consider de-indexing for drug dosing.
Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737-1749.
4 CKD-EPI 2009
eGFR = 141 × min(SCr/k, 1)^a × max(SCr/k, 1)^-1.209 × 0.993^age × 1.018 [if female] × 1.159 [if Black] Where: k = 0.7 (female) or 0.9 (male) a = -0.329 (female) or -0.411 (male)
When to use: Historical use; being replaced by the 2021 race-free version. Some older PK studies and drug labels may still reference this equation.
Limitations: Includes a race coefficient (1.159 for Black patients) that has been criticized for perpetuating health disparities. The 2021 race-free equation is now preferred.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
5 De-indexed eGFR
Absolute GFR (mL/min) = eGFR × (BSA / 1.73)
When to use: Converting BSA-indexed eGFR (mL/min/1.73 m²) to absolute GFR (mL/min) for drug dosing decisions. Essential when applying eGFR to dose drugs in patients with extreme body size.
Why it matters: Drug filtration and clearance depend on absolute glomerular filtration, not BSA-normalized values. A large patient may have a normal indexed eGFR but a high absolute GFR, and vice versa for small patients.
FDA Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function (2024); EMA Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Decreased Renal Function.
6 BSA — Mosteller Formula
BSA (m²) = √( (height [cm] × weight [kg]) / 3600 )
When to use: Required for de-indexing eGFR to absolute GFR, and for BSA-indexed CG calculations. Also used in chemotherapy dosing.
Note: The standard reference BSA is 1.73 m², derived from historical population averages. Modern adults often exceed this value.
Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.
7 Ideal Body Weight — Devine Formula
Male: IBW (kg) = 50 + 2.3 × (height in inches - 60) Female: IBW (kg) = 45.5 + 2.3 × (height in inches - 60)
When to use: Used in Cockcroft-Gault with IBW for normal-BMI patients, and as the basis for adjusted body weight calculations in obese patients. Also used in ventilator tidal-volume calculations and aminoglycoside dosing.
Limitations: Based on height only; does not capture true lean mass. Originally developed for aminoglycoside loading doses, not validated for GFR estimation.
Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650-655.
8 Adjusted Body Weight
AdjBW (kg) = IBW + 0.4 × (Actual BW - IBW)
When to use: Used in BMI-guided Cockcroft-Gault for obese patients (BMI > 30). The 0.4 correction factor accounts for the proportion of excess adipose tissue that contributes to renal clearance.
Rationale: Approximately 40% of excess body weight above IBW contributes to drug clearance. Using actual weight in obese patients overestimates CrCl; using IBW alone underestimates it.
Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Ann Pharmacother. 2012;46(9):1255-66.

CKD Staging Reference (KDIGO)

Stage GFR Range (mL/min/1.73 m²) Description Monitoring
G1 ≥ 90 Normal or high Annual SCr if risk factors present
G2 60 – 89 Mildly decreased Annual SCr; assess progression risk
G3a 45 – 59 Mildly to moderately decreased SCr every 6 months; nephrology referral if progressing
G3b 30 – 44 Moderately to severely decreased SCr every 3–6 months; begin dose adjustments for renally cleared drugs
G4 15 – 29 Severely decreased SCr every 1–3 months; nephrology co-management; prepare for RRT
G5 < 15 Kidney failure SCr every 1–3 months; dialysis or transplant evaluation; aggressive dose adjustment

Source: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. GFR categories apply when kidney damage markers are also present for G1-G2.

Key Guidelines & Publications

International Guidelines

  1. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int. 2024.
    Comprehensive update to CKD evaluation, staging, and management. Recommends CKD-EPI 2021 race-free equation for GFR estimation.
  2. FDA 2024 Guidance: Pharmacokinetics in Patients with Impaired Renal Function
    US Food and Drug Administration. Guidance for Industry. 2024.
    Updated FDA guidance recommending eGFR (CKD-EPI 2021) over Cockcroft-Gault for new PK studies. Supports de-indexed eGFR for drug dosing.
  3. EMA Guideline on the Evaluation of Pharmacokinetics in Patients with Decreased Renal Function
    European Medicines Agency. Scientific Guideline.
    European regulatory guidance on renal PK study design, GFR classification, and dose adjustment labeling for impaired renal function.
  4. NKF 2024 Consensus: Moving from Cockcroft-Gault to Race-Free eGFR for Drug Dosing
    National Kidney Foundation. Am J Health-Syst Pharm. 2024.
    Multi-stakeholder consensus recommending transition from CG to CKD-EPI 2021 for drug dosing. Outlines a practical framework for clinicians and regulators.

Original Equation Papers

  1. Prediction of creatinine clearance from serum creatinine
    Cockcroft DW, Gault MH. Nephron. 1976;16(1):31-41.
    Original derivation of the Cockcroft-Gault equation for estimating creatinine clearance from serum creatinine, age, weight, and sex.
  2. A new equation to estimate glomerular filtration rate (CKD-EPI 2009)
    Levey AS, Stevens LA, Schmid CH, et al. Ann Intern Med. 2009;150(9):604-612.
    Development of the CKD-EPI 2009 equation, providing more accurate GFR estimation than MDRD, particularly at higher GFR levels.
  3. New creatinine- and cystatin C-based equations to estimate GFR without race (CKD-EPI 2021)
    Inker LA, Eneanya ND, Coresh J, et al. N Engl J Med. 2021;385(19):1737-1749.
    Race-free reformulation of CKD-EPI. Eliminates the race coefficient while maintaining accuracy across diverse populations.
  4. Gentamicin therapy (Ideal Body Weight formula)
    Devine BJ. Drug Intell Clin Pharm. 1974;8:650-655.
    Original publication of the IBW formula widely used in pharmacy for dosing aminoglycosides and in Cockcroft-Gault weight adjustments.

Drug Dosing Evidence

  1. DOAC dosing discordance between Cockcroft-Gault and CKD-EPI
    Circ Cardiovasc Qual Outcomes.
    Demonstrates clinically significant discordance in DOAC dose recommendations when CG and CKD-EPI are used interchangeably, especially in elderly and obese patients.
  2. BMI-guided Cockcroft-Gault in hematopoietic cell transplant patients
    Pharmacotherapy. 2023.
    Evaluates the impact of different body weight inputs in Cockcroft-Gault on melphalan dose recommendations in HCT patients across BMI categories.
  3. Discordance between CG and eGFR by BMI and age categories
    Am J Kidney Dis. 2023.
    Quantifies the degree of discordance between CG-CrCl and eGFR across different BMI and age strata, highlighting populations most affected by equation choice.

RenalDose Research

  1. Estimation of renal functions for drug dosing: a narrative review
    Algendy AF et al. Narrative Review (manuscript in preparation).
    Comprehensive review of RFE methods for drug dosing, proposing the BMI-guided Cockcroft-Gault approach and graded clinical recommendations for equation selection. Foundational research behind the RenalDose algorithm.

Clinical Abbreviations Glossary

ActBW Actual Body Weight
AdjBW Adjusted Body Weight
AKI Acute Kidney Injury
ARC Augmented Renal Clearance
BMI Body Mass Index
BSA Body Surface Area
CG Cockcroft-Gault
CKD Chronic Kidney Disease
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration
CrCl Creatinine Clearance
DRD Drug Renal Dosing
eGFR Estimated Glomerular Filtration Rate
EMA European Medicines Agency
FDA Food and Drug Administration
GFR Glomerular Filtration Rate
IBW Ideal Body Weight
IDMS Isotope Dilution Mass Spectrometry
KDIGO Kidney Disease Improving Global Outcomes
mGFR Measured Glomerular Filtration Rate
NKF National Kidney Foundation
PK Pharmacokinetics
RFE Renal Function Estimation
SCr Serum Creatinine
TDM Therapeutic Drug Monitoring

See these equations in action

Run all eight renal function estimations side-by-side with the RenalDose calculator — free, instant, and evidence-based.

Open Calculator